New Insight into Diagnostic Tool for Mood Disorder
Mayo Clinic Presents the Following Video
According to the following publication, a series of proteins has been identified to offer insight into a mood disorder (Bipolar I). According to findings, these proteins could serve as diagnostic markers to identify bipolar I disorder.
It is believed that if the sample can be validated through replication, these markers may help as a new diagnostic tool in bipolar treatment.
“The potential of having a biological test to help accurately diagnose bipolar disorder would make a huge difference to medical practice,” says Mark Frye, M.D., head of psychiatry and psychology at Mayo Clinic and first author of the study. “It would then help clinicians to choose the most appropriate treatment for hard-to-diagnose individuals.”
- Read from a news release on the study.
Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders
- Translational Psychiatry (2015) 5, e689; doi:10.1038/tp.2015.185; Published online 8 December 2015
The study was conducted to determine whether proteomic profiling in serum samples can be utilized in identifying and differentiating mood disorders. A consecutive sample of patients with a confirmed diagnosis of unipolar (UP n=52) or bipolar depression (BP-I n=46, BP-II n=49) and controls (n=141) were recruited.
It is concluded that the results of this feasibility study support the possibility of developing a diagnostic test using the discovered biomarkers, which need to be validated, to help facilitate accurate diagnosis and rapid treatment initiation with improved clinical outcomes. Further functional studies of the identified proteins will increase our understanding of the pathophysiology of mood disorders, which may lead to the discovery of novel pharmacological targets.
Download the Article – Directly From the Publisher
Last Updated: 2015-12-12